Focused on Life
Providing new therapies to care-givers for diseases that currently have few or no treatment options with the aim to improve the lives of those faced with rare diseases with high unmet medical needs.
Veno Occlusive Disease or VOD, is a condition in which some of the veins in the liver are blocked as a result of cancer treatments, such as chemotherapy or radiation treatments, that are given prior to stem cell transplantation...
Get More Details
Defibrotide is Gentium’s most advanced product candidate. Two pivotal Phase II/III clinical trials with defibrotide for the treatment and prevention of VOD have been completed, a Phase III trial for treatment of severe VOD in the U.S., Canada and Israel and Phase II/III pediatric trial in Europe for the...
Product Pipeline
16 Apr 2013
Gentium to Request Re-Examination of CHMP Opinion on Defibrotide
More General News
14 May 2013
Gentium Reports First Quarter 2013 Financial Results
More Financial News
If you or your patients have suffered any adverse effects following the use of our drugs, or have found any anomalies, please contact us
Share Information
Gentium S.p.A. - P.IVA n. 02098100130